Arcturus Therapeutics (NASDAQ:ARCT) Rating Lowered to “Sell” at Wall Street Zen

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

A number of other brokerages also recently commented on ARCT. Wells Fargo & Company reduced their price objective on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, October 23rd. HC Wainwright decreased their price objective on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. Citigroup cut their target price on Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a research note on Thursday, November 13th. Leerink Partners decreased their price target on shares of Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating for the company in a research report on Friday, August 22nd. Finally, Guggenheim downgraded shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Arcturus Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $36.00.

Arcturus Therapeutics Trading Down 0.8%

Shares of Arcturus Therapeutics stock opened at $7.46 on Friday. Arcturus Therapeutics has a 12 month low of $5.85 and a 12 month high of $24.17. The stock’s fifty day moving average price is $11.10 and its 200-day moving average price is $13.89. The firm has a market cap of $211.94 million, a P/E ratio of -3.03 and a beta of 2.10.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. The company had revenue of $17.15 million for the quarter, compared to analysts’ expectations of $17.47 million. Analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Institutional Trading of Arcturus Therapeutics

Several large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in shares of Arcturus Therapeutics by 9.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 509,712 shares of the biotechnology company’s stock valued at $5,398,000 after acquiring an additional 42,636 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Arcturus Therapeutics during the 1st quarter valued at about $299,000. Invesco Ltd. grew its stake in Arcturus Therapeutics by 83.1% during the 1st quarter. Invesco Ltd. now owns 34,896 shares of the biotechnology company’s stock valued at $370,000 after purchasing an additional 15,836 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Arcturus Therapeutics in the second quarter valued at about $240,000. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Arcturus Therapeutics by 20.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 144,141 shares of the biotechnology company’s stock worth $1,526,000 after purchasing an additional 24,583 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.